picture of mastitis aetiology on a dairy unit so that therapy can be targeted most appropriately A rational approch to dry cowu therapy 2. Product selection ANDREW BRADLEY, JON HUXLEY AND MARTIN GREEN THE use of antibiotics in food-producing animals is an increasing area of public concern. In particular, the prophylactic use of antibiotics is coming under scrutiny -and antibiotic dry cow therapy is one such use. The aim of this two-part article is to provide an insight into the most important pathogens during the dry period and the best approaches to minimising their impact, through a rational approach to the prescription of dry cow therapy. Part 1, published in the last issue (November/December 2002, pp 582-587), discussed udder health priorities during the dry period. This article discusses aspects of the design, prescription, use and monitoring of antibiotic dry cow treatments. 
REVIEW OF RATIONALE
Antibiotic dry cow therapy was developed in the l950s with the aim of controlling summer mastitis. Significant research effort was directed towards achieving persistence of prophylactic levels of antibiotic in the nonlactating gland and it was this work that formed the basis of many of the products available today. It was not until the 1960s that the widespread use of antibiotic dry cow therapy was promoted as part of the newly devised 'fivepoint plan' for mastitis control. Undoubtedly, the use of dry cow therapy played no small part in the dramatic improvement in milk quality seen in the latter part of the 20th century. However, in the light of public concern over the prophylactic use of antibiotics in foodproducing animals, it would seem timely to readdress both the rationale for, and the approach to, the use of antibiotics in dry period udder health programmes.
AIMS OF ANTIBIOTIC DRY COW THERAPY
Antibiotic dry cow therapy has two broad functions: a The cure of existing intramammary infections (IMIs) present at drying off; and a The prevention of new IMIs during the dry period.
When the five-point plan was initially introduced, dry cow therapy primarily fulfilled the first of these functions, as large numbers of cows were infected with a major pathogen at drying off. However, more recently the emphasis has changed and in the majority of modern dairy herds the primary function of dry cow therapy is the prevention of new IMIs rather than the treatment of existing infections. There is good evidence to support the use of antibiotic dry cow therapy as it is well known that failure to treat cows leads to unacceptably high levels of new IMIs, and also that dry cow therapy is more effective than lactating cow therapy at combating existing IMIs (see box below). 
ROUTE OF ADMINISTRATION
The intramammary route is the route of choice for delivery of dry cow therapy. This can be supplemented by the use of systemic antibiotics, although to date there is little data available on the most appropriate timing and dosages required. The intramammary route has the advantages of being well researched, as well as allowing the delivery of high local concentrations of antibiotic; it also enables the use of antibiotics that would not normally partition to the udder when administered systemically. Its disadvantages are the risks of both physiological and anatomical damage to the streak canal and of inoculation of organisms at the time of infusion.
DESIGN CONSIDERATIONS
A detailed discussion of the pharmacokinetics of dry cow therapies is beyond the scope of this article. However, it is useful to consider some of the properties that are important in the distribution and efficacy of intramammary antibiotics.
The ideal dry cow therapy will rapidly achieve high initial concentrations throughout the udder parenchyma in order to effect a swift kill of existing pathogens; this should then be followed by a prolonged period of release of antibiotic to prevent new infections. Ideally, the antibiotic should be retained within the udder (with only limited absorption into the systemic circulation) and should then be rapidly milked out following calving.
The rate of absorption and distribution of antibiotics from an intramammary formulation is governed by a number of factors. Aluminium monosterate forms complexes with penicillins and is used along with hydrophobic globules to facilitate prolonged release of antibiotic which would otherwise be rapidly distributed and absorbed into the systemic circulation. Particle size has also been demonstrated to affect the rate and efficiency of distribution of intramammary products (Ehinger and Kietzmann 2000) and may prove beneficial in ensuring the minimum inhibitory concentration (MIC) is exceeded throughout the udder.
The distribution of drugs following intramammary administration is summarised in the table above. Absorption from the mammary gland into the systemic circulation is by passive diffusion; the rate of this diffusion is influenced by the aqueous and lipid solubilities of the drug, the degree of protein binding and the dissociation constant, pKa (which results in the 'ion trapping' of basic drugs in the udder and the rapid absorption of acidic drugs). These properties account for the rapid absorption of drugs such as the aminopenicillins and the relatively poor absorption of drugs such as dihydrostreptomycin and framycetin. Adapted from Ziv (1980) pathogens causing new IMIs during the dry period are Escherichia coli and S uberis. It is interesting to note that, despite over 30 years of extensive use of cloxacillin, there is still no recorded resistance to this antibiotic in S aureus strains isolated from milk (Booth 1997) .
As a principle of prudent use of antibiotics, it is important to select as narrow a spectrum product as possible to cure and prevent IMIs. For example, S uberis is probably most effectively treated with penicillin, while Gram-negative organisms are best treated with drugs with a specific Gram-negative spectrum. On that basis, dry cow therapy is probably one of the few instances where 'polypharmacy' is justified in order to optimise the drugs' spectrum of activity and pharmacokinetics for the combination of pathogens commonly involved.
LEVEL OF TREATMENT APPLICATION
The prescription of dry cow therapy can essentially be approached at the herd, cow or quarter level. Traditionally, treatment has often been prescribed in a blanket manner, with all cows in a herd receiving the same product. However, this is unlikely to be the most appropriate approach because it is unusual on any single farm for the same pathogen to be responsible for chronic IMIs at drying off as well as new IMIs arising during the dry period; thus, an antibiotic for treating persistent S aureus infections is unlikely to be the product of choice for preventing new coliform IMIs in the late dry period. Meanwhile, selecting treatments at the quarter level proves difficult. Not only does this approach raise practical as well as regulatory issues, but research has demonstrated chat it is unlikely to be the most costeffective means of managing IMIs in the dry period (Browning and others 1994) .
Application of dry cow therapy at the individual cow level represents the most appropriate approach to prescription. This strategy is dependent on the ability to reliably differentiate between infected and uninfected cows, a factor which becomes increasingly important if one is considering alternatives to antibiotic therapies to prevent new IMIs in cows uninfected at drying off (see later).
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The spectrum of activity of the antibiotics available in dry cow formulations against the major mastitis pathogens is summarised in the (Counter 1978) 2Streptococcus species, C bovis, A pyogenes 3Gram-negative organisms and S aureus 4108-hour milk withholding period post-calving literature, which can hamper efforts to make evidencebased decisions about product selection. * Thirdly, the 'ideal' antibiotic dry cow tube probably does not exist; there is no individual tube that offers optimal efficacy in the treatment of existing Grampositive infections coupled with suitable prolonged activity against both Gram-positive and Gram-negative organisms in the late dry period. For this reason, even in uninfected cows, it is necessary to build up a picture of mastitis aetiology on a unit so that therapy can be directed against the most prevalent pathogen at the time. In addition, it is probably prudent to supplement the antibiotic therapy with additional protective measures, such as the use of an external teat sealant.
To treat or not to treat?
Once chronically infected cows have been identified, a decision needs to be made as to whether these cows should be treated and retained, or culled. The likelihood of achieving a cure when treating an infected cow is governed by a number of factors which are outlined in the table on the right. In summary, it is likely to be difficult to achieve a cure in older cows with higher SCCs, infected in more than one quarter, in herds with poor mastitis control programmes. * Select a product with a Gram-positive spectrum of * Product selection for high SCC cows is probably relatively less activity -penicillin and its analogues are likely to provide important. A cloxacillin-based product increases the chances of the best protection against S uberis. Consideration should successfully treating any B-lactamase-producing bacteria, if they are be given to the length of the dry period when selecting present an appropriate product Farm B: Moderate BMSCC; high incidence of S uberis or Cow B: High SCC; three cases of clinical coliform coliform clinical mastitis mastitis in the previous lactation; herd evidence of * Select an appropriate product based on the organisms identified environmental mastitis of mixed aetiology in regular cultures from the high SCC cows. If S aureus is the most U Select for extended Gram-positive or Gram-negative common cause of high SCC, then consider a long-acting cloxacillin activity according to the pattern of disease identified in product. If S uberis is more important than coliforms, select for prothe herd (eg, seasonality) longed Gram-positive activity in all cows. Penicillin and its analogues * If high SCC is a result of coliform infection, the choice are likely to have the best spectrum of activity against S uberis of product is probably not an issue, as the infection is like-* When coliforms are more important, select for prolonged Gramly to be cleared by the cow's own immunity during the dry negative activity for uninfected, low SCC cows period * Consider the use of a teat sealant in uninfected cows Cow C: Low SCC; high herd incidence of clinical Farm C: High BMSCC; high incidence of S aureus; coliform mastitis problems with clinical mastitis at calving * Select for extended Gram-negative activity or use a * Select the product most likely to effect a cure of existing staphyteat sealant lococcal infections at drying off; also consider selecting a product likely to be effective against B3-lactamase-producing bacteria, such as Cow D: Low SCC; high herd incidence of clinical cloxacillin S uberis mastitis * Select for prolonged Gram-negative 
MONITORING THE USE AND SUCCESS OF DRY COW THERAPY
A strategy and protocols need to be in place to address cows that either abort or calve early following the administration of dry cow therapy, and also for identification of dry cows so as to prevent accidental contamination of the bulk tank. Preferably, there should be a standard operating procedure for cows calving early and milk should either be tested on-farm using a kit such as the DelvoSP (Gist-brocades BV, The Netherlands) or sent to a laboratory for analysis, before the cow's milk is returned to the bulk tank.
It is also important to have a strategy in place for monitoring the efficacy of dry cow therapy, both in curing existing IMIs and preventing new IMIs. It would not be cost-effective to do this using bacteriology; however, the use of the CMT or SCC records provides a viable alternative. Screening cows known to have been infected at drying off, using the CMT in the first few weeks of lactation, will facilitate the identification of persistently infected quarters/cows; management decisions can then be made (eg, culling, or changing the milking order to lower the risk of transmission of infection to other cows). Another useful way to assess the ongoing success of dry cow therapy is to monitor SCCs recorded in the last three months and first three months of lactation (see table, above right). Additional information can also be obtained from looking at the distribution of clinical mastitis cases throughout lactation; a high incidence of clinical mastitis in early lactation is probably an indication of a high level of IMIs during the dry period (Green and others 2002) . Culture of a proportion of these cases is likely to give an indication of the most important cause of new IMIs during the dry period. Using these approaches it is possible to monitor the ongoing success of dry cow therapy in a subjective manner and make logical, informed decisions about any changes to treatment strategies.
ALTERNATIVES TO ANTIBIOTIC DRY COW THERAPY
While concern over the use of antibiotics in foodproducing animals is undoubtedly growing, there are unlikely to be any viable alternatives to the use of antibiotics for the treatment of existing IMIs at drying off in the near future. In fact, it is vital that infected animals continue to receive antibiotic therapy.
However, the use of antibiotics in uninfected cows is not necessary provided an effective alternative is available for preventing the acquisition of new IMIs during the dry period. One such alternative, 'Orbeseal' (Pfizer Animal Health), an internal teat sealant, has recently been introduced in the UK. The product has been available in New Zealand for several years (Teatseal; Bimeda [NZ] ) and has been shown to be as good as antibiotic dry cow therapy in preventing new IMIs during the dry period under New Zealand field conditions (Woolford and others 1998 (Huxley and others 2002) . Appropriate selection of eligible (uninfected) cows for non-antibiotic dry cow treatments, such as internal teat sealants, is important; as discussed earlier, criteria based on historical SCC data have been successfully used to select cows likely to be uninfected with a major pathogen. Care and attention to aseptic infusion technique are vital when using any intramammary product; theoretically, this is all the more important during the infusion of internal teat sealants, as they do not contain any antibiotic.
It is important to bear in mind that antibiotic dry cow therapy and internal teat sealants are only part of a dry period udder health management programme and due consideration should always be given to factors such as fly control, environmental management, use of external teat sealants, and good nutrition.
SUMMARY
There is ample evidence to support the use of antibiotic dry cow therapy in the management of IMIs during the dry period. However, it is important to develop a rational approach to the prescription, use and monitoring of dry cow therapy and also to maximise the use of alternative strategies for reducing new IMIs during the dry period. With the advent of internal teat sealants, it is likely that the rationale for the use of high doses of long-acting antibiotics in cows uninfected with major pathogens at the time of drying off will become increasingly untenable.
